129 related articles for article (PubMed ID: 10217343)
1. Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs.
Volosov A; Sintov A; Bialer M
Ther Drug Monit; 1999 Apr; 21(2):219-23. PubMed ID: 10217343
[TBL] [Abstract][Full Text] [Related]
2. Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs.
Volosov A; Yagen B; Bialer M
Epilepsia; 2000 Sep; 41(9):1107-11. PubMed ID: 10999549
[TBL] [Abstract][Full Text] [Related]
3. Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers.
Antunes NJ; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Marques MP; Lanchote VL
J Pharm Biomed Anal; 2018 Feb; 149():442-447. PubMed ID: 29169112
[TBL] [Abstract][Full Text] [Related]
4. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL
Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.
Volosov A; Xiaodong S; Perucca E; Yagen B; Sintov A; Bialer M
Clin Pharmacol Ther; 1999 Dec; 66(6):547-53. PubMed ID: 10613609
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Flesch G; Czendlik C; Renard D; Lloyd P
Drug Metab Dispos; 2011 Jun; 39(6):1103-10. PubMed ID: 21389120
[TBL] [Abstract][Full Text] [Related]
7. Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study.
de Jesus Antunes N; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre V; Takayanagui OM; Tozatto E; Lanchote VL
Chirality; 2013 Dec; 25(12):897-903. PubMed ID: 24123382
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.
Chen X; Gu E; Wang S; Zheng X; Chen M; Wang L; Hu G; Cai JP; Zhou H
J Chromatogr Sci; 2016 Mar; 54(3):334-42. PubMed ID: 26499119
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
11. Effects of charcoal on the absorption and elimination of the antiepileptic drugs lamotrigine and oxcarbazepine.
Keränen T; Sorri A; Moilanen E; Ylitalo P
Arzneimittelforschung; 2010; 60(7):421-6. PubMed ID: 20712131
[TBL] [Abstract][Full Text] [Related]
12. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?
Di Girolamo G; Opezzo JA; Schere D; Gonzalez CD; Moncalvo JJ
Expert Opin Pharmacother; 2007 Jul; 8(10):1415-23. PubMed ID: 17661724
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
Viola MS; Bercellini MA; Saidón P; Rubio MC
Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
[TBL] [Abstract][Full Text] [Related]
14. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
[TBL] [Abstract][Full Text] [Related]
15. Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy.
Li RR; Sheng XY; Ma LY; Yao HX; Cai LX; Chen CY; Zhu SN; Zhou Y; Wu Y; Cui YM
Ther Drug Monit; 2016 Jun; 38(3):365-70. PubMed ID: 26818624
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
17. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
18. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.
Degen PH; Flesch G; Cardot JM; Czendlik C; Dieterle W
Biopharm Drug Dispos; 1994 Aug; 15(6):519-26. PubMed ID: 7993989
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
